Participants in this study will already be taking other medications for their condition but will continue on stable doses of these medicines throughout the study. The study medication or placebo will be taken daily for 12 weeks. The study is designed so that neither the participants nor the doctors will know who is receiving the actual medication and who is receiving placebo during the treatment period. The maximum daily amount of BP1.4979 that can be given is 40 milligrams.

During the study, participants will have several visits where doctors will assess how severe their obsessive compulsive symptoms are using questionnaires and rating scales. These assessments will measure things like the frequency and intensity of unwanted thoughts and repetitive behaviors, overall functioning, and mood. The doctors will also monitor for any side effects or problems that might occur during treatment. The study will help determine whether this new medication could be a useful option for treating people with moderate to severe obsessive compulsive disorder who have not responded well enough to existing treatments.

The purpose of the study is to evaluate whether Rituximab can be a clinically effective treatment for patients with these conditions. During the study, participants will receive either Rituximab or a placebo. The study will monitor changes in symptoms over time to determine the effectiveness of the treatment. Participants will be observed for improvements in their psychiatric and neurological symptoms, as well as any changes in their overall health and well-being.

The study will last for several months, with regular check-ups to assess the participants’ progress. The safety of Rituximab will also be closely monitored throughout the trial. This research aims to provide valuable insights into whether Rituximab can help patients with Psychosis or OCD when the immune system is involved, potentially leading to better treatment options in the future.

The purpose of the study is to evaluate the effectiveness of using Pramipexole as an additional treatment to boost the effects of medications known as SSRIs, which are commonly used to treat OCD. Participants in the study will receive one of three different doses of Pramipexole or a placebo. The study will last for several weeks, during which participants will take the medication and attend regular check-ups to monitor their progress and any side effects.

Throughout the study, researchers will assess changes in the severity of OCD symptoms using a specific scale designed to measure these symptoms. They will also keep track of any side effects experienced by participants. The study aims to provide valuable information on whether Pramipexole can be a helpful treatment option for people with OCD who have not found relief with other medications.

The trial will follow a cross-over design, meaning participants will receive both treatments at different times. The effects of Ketamine on OCD symptoms will be compared to those of Midazolam. The study will also look at how these treatments affect neuropsychological functions, which are brain functions related to thinking and behavior, especially under stress. Participants will be monitored for changes in their OCD symptoms and stress responses, including hormonal and physical reactions, over a period of time.

The primary goal is to observe any differences in OCD symptoms before and after receiving Ketamine compared to Midazolam. Secondary observations will include changes in stress levels and neuropsychological functions. The study will help understand the potential benefits of Ketamine for people with OCD and how it might improve their quality of life by reducing symptoms and stress-related effects.